Reuters: Regulatory News: URGENT-Agenus genital herpes vaccine succeeds in mid-stage trial

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

URGENT-Agenus genital herpes vaccine succeeds in mid-stage trial Nov 7th 2013, 12:25 Thu Nov 7, 2013 7:25am EST Nov 7 (Reuters) - Agenus Inc said a mid-stage trial of its experimental genital herpes vaccine reduced the rate at which patients' were shedding the virus. The 15 percent reduction in viral shedding in patients receiving the vaccine compared to those on a placebo, who showed no reduction. The mid-stage trial had 80 patients with a history of 1-9 herpes recurrences within the prior 12 months. Of them, 70 received the vaccine, HerpV, and 10 received placebo.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions